A Phase 3 interventional study of Saxagliptin, Onglyza and Dapagliflozin, Farxiga in Type 2 Diabetes Mellitus, sponsored by AstraZeneca. Completed at 40 sites in 10 countries. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2018-12-11.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 293 studies testing metformin in Diabetes Mellitus, Type 2 — 17 open to participants now, 22 under way, 2 of them phase 3. Metformin · Diabetes Mellitus, Type 2.
Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, this one is the 28th largest by enrollment of the 287 interventional ones that give a count, is one of 12 that started in 2015, is one of 72 in phase 3, and was the 206th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →17 of the 293 studies testing metformin in Diabetes Mellitus, Type 2 are open now, in 7 countries. Recruiting first, the newest first:
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18–75 · Men only
JW Pharmaceutical · Sites in Korea, Republic of
Ages 19+
University of California, San Francisco · Sites in United States
Ages 10–21 · Healthy volunteers
RenJi Hospital · Sites in China
Ages 18–65
Lille Catholic University · Sites in France
Ages 18–40
By country, each count listing its studies:
Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 120 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
293 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 58 · Phase 2 31 · Phase 3 77 · Phase 4 98
First in 1996; this study’s year is marked. 12 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 650 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 100 across the 287 interventional studies. Of the 235 that completed or were terminated, 89 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
155 of 293 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
345 studies in Diabetes Mellitus, Type 2 by AstraZeneca: 13 open now, 15 under way, 9 of them phase 3. Of 325 finished, 149 (46%) have results posted.
Among the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca, this one is the 50th largest by enrollment of the 280 interventional ones that give a count, is one of 15 that started in 2015, is one of 119 in phase 3, and was the 254th registered.
AstraZeneca’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
7 of the studies testing metformin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02087826Massachusetts General HospitalStudy of Clinical Response to Acute Metformin By Leveraging Evaluations During a Mixed Meal Tolerance Test for Exploring Glycemia and GeneticS | 2026-12 |
| NCT06120881University of California, San FranciscoPrecision Dosing of Metformin in Youth With T2D | 2026-12-31 |
| NCT02969798The University of Texas Health Science Center at San AntonioPre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) | 2027-02-28 |
| NCT07442006JW PharmaceuticalGlycemic Variability of Combination Therapies in T2DM | 2027-03-31 |
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, from their registry updates:
Among AstraZeneca’s 345 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This research study of subjects with inadequately controlled type 2 diabetes mellitus (T2DM) will compare the glycemic control (measured by HbA1c) in subjects co-administered saxagliptin and dapagliflozin, in addition to metformin with or without sulfonylurea, to subjects receiving insulin glargine, in addition to metformin with or without sulfonylurea, over a treatment period of 52 weeks.
CV181-369; A 24 Week International, Open-Label Trial With a 28 Week Extension to Evaluate the Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects With Type 2 Diabetes on Metformin With or Without Sulfonylurea Therapy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral route. Saxagliptin/Dapa adminsitered once daily for 24 weeks at a dose of 5 mg Saxagliptin and 10 mg Dapagliflozin
Drug: Saxagliptin, Onglyza · Drug: Dapagliflozin, Farxiga · Drug: Metformin
Insulin glargine administered once a day with starting dose of 0.2 Unit per kg or 10 units.
Drug: Glargine insulin
Tablets, Oral, 5mg , Once daily, 24 weeks
Also known as: Onglyza
Tablets, Oral, 10mg , Once daily, 24 weeks
Also known as: BMS-512148
100 Units/ml solution for injection in a prefilled SoloStar pen
Also known as: Lantus
Tablets, Oral, ≥ 1500mg/≤ 2500mg, Once daily, 24 weeks
Also known as: Glucophage
Mean Change From Baseline in HbA1c at Week 24
To examine whether the mean change from baseline in HbA1c with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin with or without SU is noninferior (noninferiority margin of 0.3%) to titrated insulin glargine plus metformin with or without SU after 24 weeks of open-label treatment.
Time frame: Baseline and Week 24
Mean Change From Baseline in Total Body Weight at Week 24
To compare the mean change from baseline in total body weight with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin with or without SU versus titrated insulin glargine plus metformin with or without SU after 24 weeks of open-label treatment
Time frame: Baseline and Week 24
Percentage of Subjects With Confirmed Hypoglycaemia at Week 24
Hypoglycemia defined as plasma glucose ≤70 mg/dL (3.9 mmol/L)
Time frame: Baseline and Week 24
Percentage of Subjects Achieving a Therapeutic Glycemic Response, Without Hypoglycaemia, at Week 24
To compare the percentage of subjects achieving a therapeutic glycemic response, defined as HbA1c \<7.0%, without any reported hypoglycemia, with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin with or without SU versus titrated insulin glargine plus metformin with or without SU after 24 weeks of open-label treatment.
Time frame: Baseline and Week 24
Percentage of Subjects Achieving a Therapeutic Glycemic Response at Week 24
To examine whether the percentage of subjects achieving a therapeutic glycemic response, defined as HbA1c \<7.0%, with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin with or without SU is noninferior (noninferiority margin of 10%) to titrated insulin glargine plus metformin with or without SU after 24 weeks of open-label treatment.
Time frame: Baseline and Week 24
Change From Baseline in the Mean Value of 24-hour Glucose at Week 2
Change from baseline in the mean value of 24-hour glucose readings measured by Continuous Glucose Monitoring with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin with or without SU is noninferior to titrated insulin glargine plus metformin with or without SU after 2 weeks of open-label treatment.
Time frame: Baseline and Week 2
This study was conducted at 112 centers in 11 countries from 20 Oct 2015 to 10 Nov 2017. There were 2 data cut-offs for this study: 8 May 2017 for analyses of the short-term study period (after 24 weeks of open-label treatment) and 10 Nov 2017 for analyses of the short-term plus long-term study period (after 52 weeks of open-label treatment).
| Milestone | Dapagliflozin + Saxagliptin + Metformin | Titrated Insulin + Metformin |
|---|---|---|
| Started | 324 | 326 |
| Received treatment in short-term study | 324 | 319 |
| Entered long-term study | 306 | 294 |
| Received treatment in long-term study | 295 | 284 |
| Completed | 296 | 287 |
| Not completed | 28 | 39 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Withdrew: Pregnancy | 0 | 1 |
| Withdrew: Reason not reported | 10 | 4 |
| Withdrew: Did not receive randomized treatment | 0 | 7 |
| Withdrew: Did not enter long-term study | 18 | 25 |
To examine whether the mean change from baseline in HbA1c with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin with or without SU is noninferior (noninferiority margin of 0.3%) to titrated insulin glargine plus metformin with or without SU after 24 weeks of open-label treatment.
| % HbA1c | Dapagliflozin + Saxagliptin + Metformin | Titrated Insulin + Metformin |
|---|---|---|
| Mean Change From Baseline in HbA1c at Week 24 | -1.67 (-1.79 to -1.55) | -1.54 (-1.66 to -1.42) |
To compare the mean change from baseline in total body weight with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin with or without SU versus titrated insulin glargine plus metformin with or without SU after 24 weeks of open-label treatment
| kg | Dapagliflozin + Saxagliptin + Metformin | Titrated Insulin + Metformin |
|---|---|---|
| Mean Change From Baseline in Total Body Weight at Week 24 | -1.50 (-1.89 to -1.11) | 2.14 (1.75 to 2.54) |
Hypoglycemia defined as plasma glucose ≤70 mg/dL (3.9 mmol/L)
| Adjusted % Participants | Dapagliflozin + Saxagliptin + Metformin | Titrated Insulin + Metformin |
|---|---|---|
| Percentage of Subjects With Confirmed Hypoglycaemia at Week 24 | 21.3 (17.03 to 26.22) | 38.4 (32.94 to 44.07) |
To compare the percentage of subjects achieving a therapeutic glycemic response, defined as HbA1c \<7.0%, without any reported hypoglycemia, with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin with or without SU versus titrated insulin glargine plus metformin with or without SU after 24 weeks of open-label treatment.
| Adjusted % Participants | Dapagliflozin + Saxagliptin + Metformin | Titrated Insulin + Metformin |
|---|---|---|
| Percentage of Subjects Achieving a Therapeutic Glycemic Response, Without Hypoglycaemia, at Week 24 | 20.9 (16.69 to 25.83) | 13.1 (9.72 to 17.33) |
To examine whether the percentage of subjects achieving a therapeutic glycemic response, defined as HbA1c \<7.0%, with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin with or without SU is noninferior (noninferiority margin of 10%) to titrated insulin glargine plus metformin with or without SU after 24 weeks of open-label treatment.
| Adjusted % Participants | Dapagliflozin + Saxagliptin + Metformin | Titrated Insulin + Metformin |
|---|---|---|
| Percentage of Subjects Achieving a Therapeutic Glycemic Response at Week 24 | 33.2 (28.00 to 38.79) | 33.5 (28.28 to 39.26) |
Change from baseline in the mean value of 24-hour glucose readings measured by Continuous Glucose Monitoring with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin with or without SU is noninferior to titrated insulin glargine plus metformin with or without SU after 2 weeks of open-label treatment.
| mg/deciliter (dL) | Dapagliflozin + Saxagliptin + Metformin | Titrated Insulin + Metformin |
|---|---|---|
| Change From Baseline in the Mean Value of 24-hour Glucose at Week 2 | -48.53 (-53.47 to -43.59) | -28.54 (-33.47 to -23.61) |
Collected over From baseline (Day 1) up to Week 52 (24-week short-term treatment period + 28-week long-term treatment period).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dapagliflozin + Saxagliptin + Metformin | 2/324 (0.6%) | 20/324 (6.2%) | 55/324 (17%) |
| Titrated Insulin + Metformin | 0/319 (0%) | 13/319 (4.1%) | 73/319 (22.9%) |
| Event | Dapagliflozin + Saxagliptin + Metformin | Titrated Insulin + Metformin |
|---|---|---|
| Coronary artery diseaseCardiac disorders | 3/324 | 1/319 |
| Acute coronary syndromeCardiac disorders | 1/324 | 2/319 |
| Cardiac failure congestiveCardiac disorders | 2/324 | 0/319 |
| ContusionInjury, poisoning and procedural complications | 1/324 | 1/319 |
| Road traffic accidentInjury, poisoning and procedural complications | 0/324 | 1/319 |
| Cerebrovascular accidentNervous system disorders | 0/324 | 1/319 |
| DepressionPsychiatric disorders | 0/324 | 1/319 |
| GangreneInfections and infestations | 0/324 | 1/319 |
| SepsisInfections and infestations | 0/324 | 1/319 |
| Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/324 | 1/319 |
| Event | Dapagliflozin + Saxagliptin + Metformin | Titrated Insulin + Metformin |
|---|---|---|
| Viral upper respiratory tract infectionInfections and infestations | 25/324 | 19/319 |
| Upper respiratory tract infectionInfections and infestations | 17/324 | 23/319 |
| HeadacheNervous system disorders | 12/324 | 22/319 |
| InfluenzaInfections and infestations | 8/324 | 16/319 |
| Age, Continuous(Years) | Dapagliflozin + Saxagliptin + Metformin | Titrated Insulin + Metformin | Total |
|---|---|---|---|
| Mean | 55.7 ± 9.52 | 55.3 ± 9.63 | 55.5 ± 9.57 |
| Sex: Female, Male(Participants) | Dapagliflozin + Saxagliptin + Metformin | Titrated Insulin + Metformin | Total |
|---|---|---|---|
| Female | 148 | 148 | 296 |
| Male | 176 | 171 | 347 |
| Race/Ethnicity, Customized(Participants) | Dapagliflozin + Saxagliptin + Metformin | Titrated Insulin + Metformin | Total |
|---|---|---|---|
| American Indian Or Alaska Native | 12 | 6 | 18 |
| Asian | 12 | 12 | 24 |
| Black Or African American | 28 | 35 | 63 |
| Native Hawaiian Or Other Pacific Islander | 0 | 1 | 1 |
| Other | 9 | 11 | 20 |
| White | 263 | 254 | 517 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2015 to primary completion in May 2017, 18 months.
Results were first posted in Sep 2018, 1 year 4 months after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 18 months is close to that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metformin